KẾT QUẢ ĐIỀU TRỊ SARCOMA XƯƠNG GIAI ĐOẠN II BẰNG HÓA CHẤT PHÁC ĐỒ MAP BỔ TRỢ TRƯỚC PHẪU THUẬT TẠI BỆNH VIỆN K

Abstract

Objectives: To evaluate the efficacy of MAP neoadjuvant chemotherapy in patients with stage II osteosarcoma. Patients and methods: Retrospective, descriptive study on 35 patients with stage II osteosarcoma who had received MAP neoadjuvant chemotherapy from 6/2019 to 06/2022 at Vietnam National Cancer Hospital. Results:  Characteristics of the study group: average age was 16.7, the male/female ratio was 1.9/1, the most common location was femur (51.4%), the most common symptom was pain (100%), swelling (62.8%). Treatment results: according to Huvos grading system based on the degree of tumor necrosis after preoperative chemotherapy showed that the good response rate (Huvos III, IV) was 51.4%, the poor response rate (Huvos I, II) was 48.6%. The rate of good response was higher in the group ≥ 14 years old, female (58.3%), although there were no statistically significant differences with p>0.05. Other factors independently related to good response include: tumor size ≤ 12cm, ALP and LDH concentration before treatment. Toxicity of the regimen included: stomatitis (25,7%), nausea (37,1%), vomiting (17,1%), liver enzymes evalated (85,7%), neutropenia (20%), creatinin evalated (2,8%), infection (2.8%). Conclusion: The MAP neoadjuvant chemotherapy improves the result of treamment while toxicities were acceptable for major patients.